Citation
Payne, Daniel C., et al. "Effectiveness of Pentavalent and Monovalent Rotavirus Vaccines in Concurrent Use Among US Children <5 Years of Age, 2009-2011." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, vol. 57, no. 1, 2013, pp. 13-20.
Payne DC, Boom JA, Staat MA, et al. Effectiveness of pentavalent and monovalent rotavirus vaccines in concurrent use among US children <5 years of age, 2009-2011. Clin Infect Dis. 2013;57(1):13-20.
Payne, D. C., Boom, J. A., Staat, M. A., Edwards, K. M., Szilagyi, P. G., Klein, E. J., Selvarangan, R., Azimi, P. H., Harrison, C., Moffatt, M., Johnston, S. H., Sahni, L. C., Baker, C. J., Rench, M. A., Donauer, S., McNeal, M., Chappell, J., Weinberg, G. A., Tasslimi, A., ... Parashar, U. D. (2013). Effectiveness of pentavalent and monovalent rotavirus vaccines in concurrent use among US children <5 years of age, 2009-2011. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 57(1), 13-20. https://doi.org/10.1093/cid/cit164
Payne DC, et al. Effectiveness of Pentavalent and Monovalent Rotavirus Vaccines in Concurrent Use Among US Children <5 Years of Age, 2009-2011. Clin Infect Dis. 2013;57(1):13-20. PubMed PMID: 23487388.
TY - JOUR
T1 - Effectiveness of pentavalent and monovalent rotavirus vaccines in concurrent use among US children <5 years of age, 2009-2011.
AU - Payne,Daniel C,
AU - Boom,Julie A,
AU - Staat,Mary Allen,
AU - Edwards,Kathryn M,
AU - Szilagyi,Peter G,
AU - Klein,Eileen J,
AU - Selvarangan,Rangaraj,
AU - Azimi,Parvin H,
AU - Harrison,Christopher,
AU - Moffatt,Mary,
AU - Johnston,Samantha H,
AU - Sahni,Leila C,
AU - Baker,Carol J,
AU - Rench,Marcia A,
AU - Donauer,Stephanie,
AU - McNeal,Monica,
AU - Chappell,James,
AU - Weinberg,Geoffrey A,
AU - Tasslimi,Azadeh,
AU - Tate,Jacqueline E,
AU - Wikswo,Mary,
AU - Curns,Aaron T,
AU - Sulemana,Iddrisu,
AU - Mijatovic-Rustempasic,Slavica,
AU - Esona,Mathew D,
AU - Bowen,Michael D,
AU - Gentsch,Jon R,
AU - Parashar,Umesh D,
Y1 - 2013/03/13/
PY - 2013/3/15/entrez
PY - 2013/3/15/pubmed
PY - 2013/12/16/medline
KW - New Vaccine Surveillance Network
KW - RotaTeq
KW - rotavirus
KW - vaccine
SP - 13
EP - 20
JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
JO - Clin Infect Dis
VL - 57
IS - 1
N2 - BACKGROUND: We assessed vaccine effectiveness (VE) for RotaTeq (RV5; 3 doses) and Rotarix (RV1; 2 doses) at reducing rotavirus acute gastroenteritis (AGE) inpatient and emergency department (ED) visits in US children. METHODS: We enrolled children <5 years of age hospitalized or visiting the ED with AGE symptoms from November 2009-June 2010 and from November 2010-June 2011 at 7 medical institutions. Fecal specimens were tested for rotavirus by enzyme immunoassay and genotyped. Vaccination among laboratory-confirmed rotavirus cases was compared with rotavirus-negative AGE controls. Regression models calculated VE estimates for each vaccine, age, ethnicity, genotype, and clinical setting. RESULTS: RV5-specific analyses included 359 rotavirus cases and 1811 rotavirus-negative AGE controls. RV1-specific analyses included 60 rotavirus cases and 155 rotavirus-negative AGE controls. RV5 and RV1 were 84% (95% confidence interval [CI], 78%-88%) and 70% (95% CI, 39%-86%) effective, respectively, against rotavirus-associated ED visits and hospitalizations combined. By clinical setting, RV5 VE against ED and inpatient rotavirus-associated visits was 81% (95% CI, 70%-84%) and 86% (95% CI, 74%-91%), respectively. RV1 was 78% (95% CI, 46%-91%) effective against ED rotavirus disease; study power was insufficient to evaluate inpatient RV1 VE. No waning of immunity was evident during the first 4 years of life for RV5, nor during the first 2 years of life for RV1. RV5 provided genotype-specific protection against each of the predominant strains (G1P[8], G2P[4], G3P[8], G12P[8]), while RV1 VE was statistically significant for the most common genotype, G3P[8]. CONCLUSIONS: Both RV5 and RV1 significantly protected against medically attended rotavirus gastroenteritis in this real-world assessment.
SN - 1537-6591
UR - https://www.unboundmedicine.com/medline/citation/23487388/Effectiveness_of_pentavalent_and_monovalent_rotavirus_vaccines_in_concurrent_use_among_US_children_<5_years_of_age_2009_2011_
L2 - https://academic.oup.com/cid/article-lookup/doi/10.1093/cid/cit164
DB - PRIME
DP - Unbound Medicine
ER -